Dr. Levy on the Treatment of T790M-Mutant Lung Cancer

Benjamin P. Levy, MD
Published: Friday, Dec 29, 2017



Benjamin P. Levy, MD, assistant professor of oncology, clinical director of medical oncology, Johns Hopkins Sidney Kimmel Cancer Center, Johns Hopkins Medicine, discusses the treatment options for patients with T790M-mutant lung cancer.

According to Levy, patients who progress on first- or second-generation tyrosine kinase inhibitors (TKIs) should be tested for T790M. T790M can be tested in blood and tissue but data suggest that the physician should start with a blood test.

If the patient is positive for T790M, osimertinib (Tagrisso) is approved for the treatment of those patients, says Levy.



Benjamin P. Levy, MD, assistant professor of oncology, clinical director of medical oncology, Johns Hopkins Sidney Kimmel Cancer Center, Johns Hopkins Medicine, discusses the treatment options for patients with T790M-mutant lung cancer.

According to Levy, patients who progress on first- or second-generation tyrosine kinase inhibitors (TKIs) should be tested for T790M. T790M can be tested in blood and tissue but data suggest that the physician should start with a blood test.

If the patient is positive for T790M, osimertinib (Tagrisso) is approved for the treatment of those patients, says Levy.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Working Group to Optimize Outcomes in EGFR-mutated Lung Cancers: Evolving Concepts for Nurses to Facilitate and Improve Patient CareJun 30, 20181.5
Community Practice Connections™: 4th Annual Miami Lung Cancer Conference®Jun 30, 20187.0
Publication Bottom Border
Border Publication
x